NEWS
View news from our Featured Companies.
NeurAxis Announces New Medical Policy Coverage in North Dakota
CARMEL, Ind., April 23, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the...
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
Tru Niagen® expands to health-conscious Sprouts consumers in more than 400 locations across 23 states LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its...
Zoomd to Report Fourth Quarter and Full Year 2023 Financial Results on April 24th
Conference call to be conducted on Wednesday, April 24, at 11 a.m. ET. VANCOUVER, BC, April 22, 2024 -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology...
Precision Optics Announces Receipt of $720,000 Follow-On Production Order from Top Tier Defense/Aerospace Customer for New Optical Application
GARDNER, Mass., April 18, 2024 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced it has received a $720,000 follow on production order from...
Mogo Reiterates Support for KAOS Capital’s Call for Change at WonderFi
VANCOUVER, British Columbia - Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) ("Mogo" or the "Company"), today reiterated the Company's support for KAOS Capital Inc. ("KAOS") and its call for change at WonderFi Technologies Inc. ("WonderFi") (TSX:WNDR), including KAOS's intention...
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
SARASOTA, Fla., April 16, 2024 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and...
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
- RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia - - Initiation of registrational RECOVER-2 trial expected in the second quarter of 2024;...
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia - - Topline data from 1-year...
Scientific Industries Announces Appointment of Industry Leader Michael Blechman as New Board Member
BOHEMIA, NY / April 16, 2024 / Scientific Industries, Inc. (OTCQB:SCND) ("SI") announced the appointment of Michael Blechman to the Board of Directors of SI effective April 12, 2024. Mr. Blechman filled a Board vacancy and replaces Mr. Marcus Frampton, who recently...
Jewett-Cameron Announces 2nd Quarter Financial Results
NORTH PLAINS, Ore., April 15, 2024 -- Jewett-Cameron Trading Company Ltd. (NASDAQ: JCTCF) today reported financial results for the second quarter and six month periods of fiscal 2024 ended February 29, 2024. Sales for the second quarter of fiscal 2024 were $8.23...
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
PONTE VEDRA, Fla., April 11, 2024 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to...
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
Encinitas, California--(April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating functional vision assessments for patients with profound blindness. Functional...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
PORTLAND, Maine, April 09, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
CARMEL, Ind., April 09, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the...
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for tecarfarin PONTE VEDRA, Fla., April 9, 2024 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing...
Greenfire Resources to Participate and Present at the BMO Capital Markets & CAPP Energy Symposium
Calgary, Alberta--(April 8, 2024) - Greenfire Resources Ltd. (NYSE: GFR) (TSX: GFR) ("Greenfire" or the "Company"), a Calgary-based energy company focused on the sustainable production and development of thermal energy resources from the Athabasca region of Alberta,...
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
Encinitas, California--(April 5, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentations from two upcoming investor conferences.Kiora will present at The 23rd Annual Needham Virtual Healthcare Conference on April 11th,...
InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K
ROCHESTER HILLS, Mich. - InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced...
ARIANNE PHOSPHATE CAPS ROYALTY BUYBACK AND ISSUES SHARES AS INTEREST PAYMENT
DAN: TSX-V (Canada)JE9N: FSE (Germany)DRRSF: OTCQX (USA) SAGUENAY, QC, April 2, 2024 /CNW/ - Arianne Phosphate (the "Company" or "Arianne") (TSXV: DAN) (OTCQX: DRRSF) (FRANKFURT: JE9N), a development-stage phosphate mining company, advancing the Lac à Paul...
SenesTech to Present at the Emerging Growth Conference on April 3, 2024
Webcasted presentation to take place at 3:10pm ET PHOENIX, April 2, 2024 -- SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, today announced that its Chief Executive Officer, Joel Fruendt, will be participating in the...
Scientific Industries to Host Full Year 2023 Financial Results Investor Call on April 3, 2024
Investor Call to be held at 11:00 AM Eastern TimeBOHEMIA, NY / April 1, 2024 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced today it filed a Form 10K on March 29,...
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024
CARMEL, Ind., April 01, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial...
Scientific Industries Reports Financial Results for Full Year Ended December 31, 2023 and Launches New VIVID-LITE S Pill Counter
Investor Conference Call to be held at 11:00 a.m. ET on April 3, 2024BOHEMIA, NY / April 1, 2024 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, reported financial results for...
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
CUPERTINO, Calif., March 28, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Encinitas, California--(March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accepted for presentation at the Association for Research in Vision and Ophthalmology...